Actimmune is a synthetic version of interferon gamma-1b, a naturally occurring biologic response modifier. FDA has approved Actimmune to decrease the number and severity of infections in patients with chronic granulomatous disease and to delay the progression of severe, malignant osteopetrosis.
Adverse reactions or quality problems experienced with the use of this drug may be reported to the FDA's MedWatch Adverse Event Reporting program using the contact information at the bottom of this page.
Information for Healthcare Professionals: Interferon gamma-1b (marketed as Actimmune)[ARCHIVED]
- Public Health Advisory: Interferon gamma-1b (marketed as Actimmune) [ARCHIVED]